SOUTH SAN FRANCISCO, CA – Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for cancer, announced the… Read More
Launch enables efficient and scalable electroporation across research applications up to GMP manufacturing New system includes optimized cartridge design for improved performance for CRISPR-based knock-out, knock-in and transposition BASEL, CH… Read More
Media advisory Launch enables efficient and scalable electroporation across research applications up to GMP manufacturing New system includes optimized cartridge design for improved performance for CRISPR-based knock-out, knock-in and… Read More
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA® is FDA approved to treat schizophrenia… Read More
Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY® Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients… Read More
